A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 4 Information on the Company A.History and Development of the Company We were organized under the laws of the Kingdom of Denmark in September 2006 as a private limited liability company (Anpartsselskab, or ApS) and then transformed into a public limited liability company (Aktieselskab, or A/S), effective December 17, 2007. In connection with this conversion, our legal name changed from Ascendis Pharma ApS to Ascendis Pharma A/S. We commenced operations in December 2007 in connection with the acquisition of the company that invented our TransCon technologies, Complex Biosystems GmbH. Our registered office and principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark and our telephone number is +45 70 22 22 44. Our agent for service of process in the United States is Ascendis Pharma, Inc., located at 1000 Page Mill Road. Palo Alto, CA 94304. Our corporate website address is www.ascendispharma.com.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 815M | 815M | 393M | 290M | - | - |
| Net Income | -258M | -258M | -408M | -523M | -614M | -453M |
| EPS | $-4.20 | $-4.20 | $-6.97 | $-9.17 | $-10.82 | $-8.16 |
| Free Cash Flow | 61M | 61M | -331M | -507M | -522M | -521M |
| ROIC | -8.3% | -10.5% | -23.6% | - | -168.5% | -43.4% |
| Gross Margin | 86.8% | 86.8% | 87.8% | 83.4% | - | - |
| Debt/Equity | 0.00 | -2.64 | -4.33 | - | - | - |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -154M | -154M | -301M | -495M | -592M | -533M |
| Operating Margin | -18.9% | -18.9% | -76.7% | -170.8% | - | - |
| ROE | 0.0% | - | - | -818.4% | -101.7% | -44.5% |
| Shares Outstanding | 61M | 61M | 59M | 57M | 57M | 55M |
Ascendis Pharma A/S passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 86.0%.
Ascendis Pharma A/S (ASND) has a 5-year average return on invested capital (ROIC) of -61.5%. This is below average and may indicate limited pricing power.
Ascendis Pharma A/S (ASND) has a market capitalization of $15.3B. It is classified as a large-cap stock.
Ascendis Pharma A/S (ASND) does not currently pay a regular dividend.
Ascendis Pharma A/S (ASND) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Ascendis Pharma A/S (ASND) reported annual revenue of $815 million in its most recent fiscal year, based on SEC EDGAR filings.
Ascendis Pharma A/S (ASND) has a net profit margin of -31.7%. The company is currently unprofitable.
Ascendis Pharma A/S (ASND) generated $61 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Ascendis Pharma A/S (ASND) reported earnings per share (EPS) of $-4.20 in its most recent fiscal year.
Ascendis Pharma A/S (ASND) has a 5-year average gross margin of 86.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 11 years of financial data for Ascendis Pharma A/S (ASND), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Ascendis Pharma A/S (ASND) has a book value per share of $-3.00, based on its most recent annual SEC filing.